Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by AKAMPION
< Previous
1
2
3
Next >
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
April 15, 2025
From
AKAMPION
Via
GlobeNewswire
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
April 09, 2025
From
AKAMPION
Via
GlobeNewswire
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
March 24, 2025
From
AKAMPION
Via
GlobeNewswire
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
February 25, 2025
From
AKAMPION
Via
GlobeNewswire
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
January 08, 2025
From
AKAMPION
Via
GlobeNewswire
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
January 07, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
December 09, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
December 04, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
November 19, 2024
From
AKAMPION
Via
GlobeNewswire
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
November 11, 2024
From
AKAMPION
Via
GlobeNewswire
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
October 23, 2024
From
AKAMPION
Via
GlobeNewswire
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
October 09, 2024
From
AKAMPION
Via
GlobeNewswire
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
September 24, 2024
From
AKAMPION
Via
GlobeNewswire
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024
From
AKAMPION
Via
GlobeNewswire
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
July 24, 2024
From
AKAMPION
Via
GlobeNewswire
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
June 12, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
June 11, 2024
From
AKAMPION
Via
GlobeNewswire
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
June 05, 2024
From
AKAMPION
Via
GlobeNewswire
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
May 28, 2024
From
AKAMPION
Via
GlobeNewswire
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
May 22, 2024
From
AKAMPION
Via
GlobeNewswire
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07, 2024
From
AKAMPION
Via
GlobeNewswire
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
April 29, 2024
From
AKAMPION
Via
GlobeNewswire
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
April 23, 2024
From
AKAMPION
Via
GlobeNewswire
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
April 03, 2024
From
AKAMPION
Via
GlobeNewswire
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
March 13, 2024
From
AKAMPION
Via
GlobeNewswire
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
March 05, 2024
From
AKAMPION
Via
GlobeNewswire
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
February 20, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
February 06, 2024
From
AKAMPION
Via
GlobeNewswire
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
January 31, 2024
From
AKAMPION
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
